Lyon Street Capital LLC Acquires 28,312 Shares of Concert Pharmaceuticals Inc (CNCE)

Lyon Street Capital LLC boosted its holdings in shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) by 6.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 463,064 shares of the biotechnology company’s stock after acquiring an additional 28,312 shares during the quarter. Concert Pharmaceuticals makes up approximately 2.6% of Lyon Street Capital LLC’s portfolio, making the stock its 12th largest holding. Lyon Street Capital LLC owned 2.03% of Concert Pharmaceuticals worth $6,830,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Concert Pharmaceuticals by 11.0% in the second quarter. Vanguard Group Inc. now owns 756,513 shares of the biotechnology company’s stock valued at $10,553,000 after purchasing an additional 74,801 shares during the period. Northern Trust Corp raised its position in shares of Concert Pharmaceuticals by 11.2% in the second quarter. Northern Trust Corp now owns 243,989 shares of the biotechnology company’s stock valued at $3,403,000 after purchasing an additional 24,622 shares during the period. Geode Capital Management LLC raised its position in shares of Concert Pharmaceuticals by 0.6% in the first quarter. Geode Capital Management LLC now owns 142,740 shares of the biotechnology company’s stock valued at $2,435,000 after purchasing an additional 838 shares during the period. Schwab Charles Investment Management Inc. raised its position in shares of Concert Pharmaceuticals by 47.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 32,122 shares of the biotechnology company’s stock valued at $449,000 after purchasing an additional 10,400 shares during the period. Finally, Alps Advisors Inc. raised its position in shares of Concert Pharmaceuticals by 6.3% in the second quarter. Alps Advisors Inc. now owns 20,362 shares of the biotechnology company’s stock valued at $284,000 after purchasing an additional 1,200 shares during the period. 65.36% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities analysts have recently commented on CNCE shares. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Concert Pharmaceuticals in a research report on Monday, September 18th. ValuEngine raised shares of Concert Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. TheStreet raised shares of Concert Pharmaceuticals from a “d” rating to a “c+” rating in a research report on Wednesday, November 29th. Finally, Mizuho started coverage on shares of Concert Pharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $23.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $23.00.

Shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) opened at $23.47 on Wednesday. Concert Pharmaceuticals Inc has a 52 week low of $7.11 and a 52 week high of $25.41.

In other news, insider Ryan Lynch sold 3,500 shares of the firm’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $14.51, for a total value of $50,785.00. Following the sale, the insider now owns 9,500 shares in the company, valued at $137,845. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Value Fund L. P. Biotechnology acquired 331,916 shares of the stock in a transaction dated Thursday, October 19th. The stock was bought at an average price of $15.84 per share, for a total transaction of $5,257,549.44. The disclosure for this purchase can be found here. Company insiders own 10.10% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Lyon Street Capital LLC Acquires 28,312 Shares of Concert Pharmaceuticals Inc (CNCE)” was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright laws. The original version of this story can be read at https://stocknewstimes.com/2017/12/06/lyon-street-capital-llc-acquires-28312-shares-of-concert-pharmaceuticals-inc-cnce.html.

About Concert Pharmaceuticals

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Want to see what other hedge funds are holding CNCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Concert Pharmaceuticals Inc (NASDAQ:CNCE).

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Ratings for Concert Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply